Japan· JP-1319756Q1065
タフルプロスト
A tafluprost product containing タフルプロスト, registered in Japan by ロートニッテン, on the national reimbursement list. The same ATC class is registered in 16 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Tafluprost is registered in 16 of 19 countries.
Countries holding a registration under ATC S01EE05 (tafluprost), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 9 of them publish a price we can compare per daily dose
Tafluprost · ATC S01EE05
16 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- タフルプロスト
- Manufacturer
- ロートニッテン
- Country
- Japan (JP)
- ATC code
- S01EE05
- ATC class
- Tafluprost
- Defined daily dose
- 0.1 ml, AT
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under S01EE05
Tafluprost, as other registers publish it.
- ItalySAFLUROUND*collirio 1 flaconcino 15 mcg/ml 3 mlSANTEN OY
- DenmarkSaflutanOrifarm A/S
- DenmarkSaflutan2care4 ApS
- NetherlandsSaflutan 15 microgram/ml oogdruppels, oplossingSanten Oy
- NetherlandsSaflutan 15 microgram/ml oogdruppels, oplossing, verpakking voor eenmalig gebruikBModesto B.V.
- NetherlandsSaflutan 15 microgram/ml, oogdruppels, oplossing, verpakking voor eenmalig gebruikEuro Registratie Collectief B.V.
- NetherlandsSaflutan 15 microgram/ml, oogdruppels, oplossing, verpakking voor eenmalig gebruikEuro Registratie Collectief B.V.
- NetherlandsSaflutan 15 microgram/ml, oogdruppels, oplossing, verpakking voor eenmalig gebruikSanten Oy
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b2b8f56a-6000-4642-a993-3319e2046279 GET /v1/drugs/b2b8f56a-6000-4642-a993-3319e2046279?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "０．００１５％１ｍＬ",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "1319756Q1065",
"category": "外用薬",
"price_yen": 242.2,
"generic_name": "タフルプロスト",
"product_name_jp": null,
"therapeutic_class": "1319",
"transitional_expiry": null
}See everything about tafluprost.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.